Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports.

Published on Dec 17, 2020in Case Reports in Oncology
· DOI :10.1159/000510894
Tomoyuki Araya7
Estimated H-index: 7
,
Toshiyuki Kita15
Estimated H-index: 15
+ 3 AuthorsKazuo Kasahara28
Estimated H-index: 28
Source
Abstract
A standard chemotherapy regimen for advanced thymic carcinoma has not yet been established. We treated 2 cases of thymic carcinoma with carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel, and nab-paclitaxel maintenance therapy. The first case was a 68-year-old female, admitted for dyspnea and left shoulder pain. Chest computed tomography (CT) showed a huge mass in the anterior mediastinum, pleural and pericardial effusions, and multiple lung metastases. Specimens obtained from the anterior mediastinal mass by CT-guided needle biopsy revealed squamous cell carcinoma of the thymus, which was in stage IVB. The patient was administered carboplatin plus nab-paclitaxel as first-line treatment. After 3 cycles of chemotherapy, a partial response was observed with marked shrinkage of the tumor. Following 6 cycles of chemotherapy, nab-paclitaxel maintenance therapy was initiated. Disease progression was seen 9.1 months after initiation of treatment. The patient experienced no serious adverse events. The second case was a 70-year-old male who had productive cough, dyspnea, and right-sided chest pain. Chest CT revealed a huge mass in the anterior mediastinum, pericardial effusion, and multiple lymphadenopathies. Specimens obtained from station 11s by endobronchial ultrasound-guided transbronchial needle aspiration revealed undifferentiated thymic carcinoma, which was in stage IVB. Six cycles of carboplatin plus nab-paclitaxel were administered, followed by 5 cycles of nab-paclitaxel for maintenance. A partial response was seen, which was sustained for more than 13 months. The patient experienced no serious adverse events. These cases show that chemotherapy with carboplatin plus nab-paclitaxel and nab-paclitaxel as maintenance therapy can be a useful regimen for advanced thymic carcinoma.
References14
Newest
#1Akira Nakao (Fukuoka University)H-Index: 3
#2Junji Uchino (Kyoto Prefectural University of Medicine)H-Index: 15
Last. Masaki Fujita (Fukuoka University)H-Index: 28
view all 18 authors...
Background A global multicenter study demonstrated superiority of carboplatin + nab-paclitaxel (PTX) therapy compared to carboplatin + PTX in terms of response rate (RR) and non-inferiority in terms of progression free survival (PFS) and overall survival (OS) in untreated patients with stage IIIB/IV non-small cell lung cancer; no clinical findings have so far been reported on maintenance therapies with nab-PTX. The aim of this study was to determine the efficacy and safety of maintenance therapy...
2 CitationsSource
#1Kunihiko FunaishiH-Index: 3
#2Masahiro YamasakiH-Index: 21
Last. Nobuyuki OhashiH-Index: 5
view all 8 authors...
Thymic carcinomas are rare malignant tumors, located in the anterior mediastinum. For the treatment of these carcinomas, several chemotherapy regimens have been suggested, including carboplatin plus p
1 CitationsSource
#1Jun Nakajima (UTokyo: University of Tokyo)H-Index: 44
#2Meinoshin Okumura (Osaka University)H-Index: 67
Last. Yoshifumi Sano (Ehime University)H-Index: 28
view all 7 authors...
Abstract Myasthenia gravis (MG) has been reported to correlate with earlier stage and Type B thymomas by the World Health Organization classification. We analysed a large database of clinical characteristics of patients with MG and thymic epithelial tumours to elucidate whether the severity of MG affected postoperative survival of those with thymic epithelial neoplasms. We conducted a multi-institutional study on the patients who had undergone surgical treatment for thymic epithelial tumours bet...
20 CitationsSource
#1Hiroshi Shima (Kyoto University)H-Index: 5
#2Hiroaki Ozasa (Kyoto University)H-Index: 14
Last. Michiaki Mishima (Kyoto University)H-Index: 76
view all 11 authors...
Thymic carcinoma is a rare neoplasm with a poor outcome due to its aggressive characteristics. For patients who are not operable, radiation therapy and/or palliative chemotherapy are indicated. However, no optimal chemotherapy regimen has been established. The present study reports the case of a 22-year-old man with advanced lymphoepithelioma-like thymic carcinoma refractory to conventional chemotherapy with carboplatin plus solvent-based paclitaxel (sb-PAC) treatment. The patient was subsequent...
4 CitationsSource
#1Jianping Xu (Peking Union Medical College)H-Index: 5
#2Xuezhi Hao (Peking Union Medical College)H-Index: 10
Last. Yuankai Shi (Peking Union Medical College)H-Index: 31
view all 5 authors...
This study aimed to assess the efficacy and safety of a combination of paclitaxel and cisplatin/carboplatin for the treatment of advanced thymic carcinoma. Thirty-seven patients (23 men and 14 women, median age 47 years, performance status score ≤2) with pathologically or cytologically diagnosed advanced thymic carcinoma were recruited. Patients received 175 mg/m2 paclitaxel on day 1 and 75 mg/m2 cisplatin or 300 mg/m2 carboplatin on day 2 of a 21 day cycle for at least two cycles to evaluate ef...
5 CitationsSource
#1Satoshi Igawa (Kitasato University)H-Index: 15
#2Nobuyuki Yanagisawa (Kitasato University)H-Index: 15
Last. Noriyuki Masuda (Kitasato University)H-Index: 29
view all 10 authors...
Thymic large cell neuroendocrine carcinomas (LCNECs) are rare, and the optimal regimen for second and subsequent lines of chemotherapy for the treatment of LCNECs remains unknown. In the present case study, a 59-year-old male with post-operative recurrent thymic LCNEC was treated with nab-paclitaxel and carboplatin every 4 weeks as third-line chemotherapy, and a partial response was achieved following 4 cycles of this regimen. The patient developed grade 4 neutropenia and grade 3 leukopenia, but...
6 CitationsSource
#1Fumihiko HiraiH-Index: 19
#2Takeharu Yamanaka (YCU: Yokohama City University)H-Index: 37
Last. Yoichi Nakanishi (Kyushu University)H-Index: 64
view all 17 authors...
Abstract Thymic carcinoma (TC) is an exceptionally rare tumor, which has a very poor prognosis differing from thymoma. Till date, there has been no report of any results of clinical trials focusing on TC. The role of non-anthracycline-based chemotherapy has not been elucidated since the previous studies included a relatively small number of TC patients. This single-arm study evaluated carboplatin and paclitaxel (CbP) in chemotherapy-naive patients with advanced TC. The study treatment consisted ...
40 CitationsSource
#1Go MakimotoH-Index: 7
#1Go Makimoto (Nagara Medical Center)H-Index: 2
Last. Takuo ShibayamaH-Index: 17
view all 10 authors...
We present the case of a 40-year-old man with previously treated thymic carcinoma, complaining of gradually worsening back pain. Computed tomography scans of the chest showed multiple pleural disseminated nodules with a pleural effusion in the right thorax. The patient was treated with carboplatin on day 1 plus nab-paclitaxel on day 1 and 8 in cycles repeated every 4 weeks. Objective tumor shrinkage was observed after 4 cycles of this regimen. In addition, the elevated serum cytokeratin 19 fragm...
4 CitationsSource
#1Mark A. Socinski (UNC: University of North Carolina at Chapel Hill)H-Index: 77
#2Igor BondarenkoH-Index: 62
Last. Markus F. RenschlerH-Index: 17
view all 12 authors...
Purpose This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced non– small-cell lung cancer (NSCLC). Patients and Methods In all, 1,052 untreated patients with stage IIIB to IV NSCLC were randomly assigned 1:1 to receive 100 mg/m 2 nab-paclitaxel weekly and carboplatin at area under the concentration-time curve (AUC) 6 once every 3 weeks (nab-PC) or 200 mg/m 2 sb...
448 CitationsSource
#1Makoto FurugenH-Index: 1
#2Ikuo SekineH-Index: 46
Last. Tomohide TamuraH-Index: 78
view all 8 authors...
Objective: Thymic carcinoma is a rare cancer of the thymus, different from thymoma in respect of its malignant nature, and no standard chemotherapy for this cancer has been established yet. Methods: We conducted a retrospective review of the efficacy of combination chemotherapy with carboplatin (an area under the curve of 6) and paclitaxel (200 mg/m 2 ) in 16 patients with histologically or cytologically proven thymic carcinoma, Masaoka Stage IVa/IVb or postoperative recurrent disease. Results: ...
28 CitationsSource
Cited By0
Newest